The Critical Role of Pediatric Clinicians in Achieving Best Practices in Atopic Dermatitis Assessment, Management, and Referral

 

 

PROGRAM OVERVIEW

Atopic dermatitis (AD) is a chronic relapsing and remitting inflammatory skin disease that affects 7.2% of adults and 12% of children. Disability and a poor quality of life (QOL) are associated with AD, particularly among patients who are suboptimally managed. Pediatricians and primary care providers (PCPs) are often the first point-of-contact for patients with AD.

Although PCPs and pediatricians are seeing an increase in AD cases, recent evidence shows these clinicians are lacking in their ability to accurately diagnose and assess disease severity. In a recent survey, only 29% of PCPs were able to recognize essential features and characteristic distribution of AD to support diagnosis. Another survey found a discrepancy between how physicians and patients rate AD severity, with patients focusing more on skin-related QOL outcomes and physicians focusing more on sleep disturbance. Many moderate-to-severe cases of AD in adulthood often begin as early-onset disease that was suboptimally treated or miscategorized. This activity will address these educational gaps among PCPs and pediatricians, and application of the knowledge gained will improve outcomes for patients with AD.

FACULTY

Peter Lio, MD
Clinical Assistant Professor​
Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine​
Founding Director
Chicago Integrative Eczema Center
Chicago, Illinois

 

Release date: September 30, 2021
Expiration date: September 30, 2022
Estimated time to complete activity: 1 hour

 

TARGET AUDIENCE

This educational initiative has been designed for pediatricians and pediatric nurse practitioners involved in the management of patients with AD.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Integrate evidence-based diagnostic criteria and assessment strategies into the routine identification and evaluation of children and adults with known or suspected AD
  • Apply current guideline recommendations to the effective management of children and adults with AD
  • Review safety and efficacy data on new and emerging therapies for children and adults with AD
  • Demonstrate prompt referral of patients with AD to specialist care in accordance with guideline recommendations and best practices
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 30, 2021 through September 30, 2022 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Peter Lio, MD
Speaker: Eli Lilly, Galderma, LEO, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme
Advisory Board: AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN Pharmaceuticals, Bodewell, Burt’s Bees, Dermavant, Eli Lilly, Exeltis, Galderma, IntraDerm, Johnson & Johnson, Kimberly-Clark, KPAway, LEO Pharmaceuticals, Level Ex, L’Oréal, Menlo Therapeutics, Micreos, My-Or Diagnostics, Pfizer, Pierre-Fabre, Regeneron/Sanofi Genzyme, Theraplex, Unilever, Verrica, YobeeCare
Research: AbbVie, AOBiome, Regeneron/Sanofi Genzyme
Patent Holder: Theraplex AIM (Patent Pending)
Stockholder: Altus Labs, KPAway, LearnSkin, Micreos, YobeeCare

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc..

SUPPORTER ACKNOWLEDGEMENT

This activity is supported by an independent medical education grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Continue to Pretest